Lung Cancer最新文献

{"title":"Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis","authors":"Hidetoshi Hayashi ,&nbsp;Byoung Chul Cho ,&nbsp;Yu Jung Kim ,&nbsp;Se-Hoon Lee ,&nbsp;Pongwut Danchaivijitr ,&nbsp;Adlinda Alip ,&nbsp;Hailin Xiong ,&nbsp;Soon-Hin How ,&nbsp;Gee-Chen Chang ,&nbsp;James Chih-Hsin Yang ,&nbsp;Yuta Yamanaka ,&nbsp;Mehmet Ali Nahit Şendur ,&nbsp;Kumar Prabhash ,&nbsp;Koichi Azuma ,&nbsp;Alianu Akawung ,&nbsp;Elizabeth Fennema ,&nbsp;Xiaodan Tang ,&nbsp;Sujay Shah ,&nbsp;Seema Sethi ,&nbsp;Shun Lu","doi":"10.1016/j.lungcan.2026.109305","DOIUrl":"10.1016/j.lungcan.2026.109305","url":null,"abstract":"<div><h3>Background</h3><div>Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line <em>EGFR</em>-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) analysis of MARIPOSA (NCT04487080), amivantamab-lazertinib showed a statistically significant and clinically meaningful improvement in OS versus osimertinib (HR, 0.75; <em>P</em> = 0.005) among all participants. We evaluated OS for amivantamab-lazertinib versus osimertinib in Asian participants.</div></div><div><h3>Patients and methods</h3><div>Participants with previously untreated <em>EGFR</em>-mutated, locally advanced/metastatic NSCLC were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib, or lazertinib (for evaluating contribution of components). Self-identified Asian race was a stratification factor. OS was a key secondary endpoint.</div></div><div><h3>Results</h3><div>Of 1074 randomized participants, 629 self-identified as Asian (amivantamab-lazertinib:250; osimertinib:251; lazertinib:128). At a median follow-up of 38.7 months, amivantamab-lazertinib significantly prolonged OS versus osimertinib among Asian participants. Median OS was not reached (NR; 95 % CI, NR–NR) for amivantamab-lazertinib versus 38.4 months (95 % CI, 35.1–NR) for osimertinib (HR, 0.74; 95 % CI, 0.56–0.97; nominal <em>P</em> = 0.026). Assuming exponential distribution of OS in both arms, amivantamab-lazertinib is projected to prolong median OS among Asian participants by &gt; 12 months versus osimertinib. At 36 months, 61 % and 53 % were alive in the amivantamab-lazertinib and osimertinib arms. Safety profile was consistent with the overall population.</div></div><div><h3>Conclusions</h3><div>Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated <em>EGFR</em>-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109305"},"PeriodicalIF":4.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database","authors":"Jiesong Wang ,&nbsp;Xue Wang ,&nbsp;Yaxin Li ,&nbsp;Chunxia Huang ,&nbsp;Xiaopeng Xu ,&nbsp;Mei Zhang","doi":"10.1016/j.lungcan.2025.108801","DOIUrl":"10.1016/j.lungcan.2025.108801","url":null,"abstract":"<div><h3>Objectives</h3><div>Tarlatamab (Imdelltra, AMG757) has been approved for extensive-stage small cell lung cancer (ES-SCLC) treatment, yet post-marketing data remain limited. Existing studies lack conclusive evidence on its real-world safety profile.</div></div><div><h3>Materials and methods</h3><div>Leveraging the FDA Adverse Event Reporting System (FAERS), this study evaluated adverse events (AEs) attributed to Tarlatamab between Q2 2024 and Q1 2025. Disproportionality analysis using reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) quantified associations between Tarlatamab and AEs.</div></div><div><h3>Results</h3><div>Among 448 analyzed AE reports, the median time to AE onset was 5.0 days. Tarlatamab-associated AEs reports showed elevated hospitalization (21.7 %) and fatality rates (16.7 %). Significant signals emerged across 5 System Organ Classes (SOCs) and 31 Preferred Terms (PTs), including unlabeled events: atrial fibrillation (IC025: 0.77), ageusia (IC025: 3.79), mental status changes (IC025: 2.45), and unresponsiveness to stimuli (IC025: 2.22). Notable discrepancies with labeled information included dual hypertension (IC025: 0.18) and hypotension (IC025: 1.61) signals, suggesting complex blood pressure effects, and a higher mortality risk in male patients. Mild AEs correlated with reduced severe outcome risks.</div></div><div><h3>Conclusion</h3><div>These findings offer critical insights for clinicians to identify and manage Tarlatamab-related AEs, highlighting underestimated risks and informing tailored practice.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 108801"},"PeriodicalIF":4.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action","authors":"Laura Alder ,&nbsp;Trey C. Mullikin ,&nbsp;Chris Lascola ,&nbsp;Paul W. Sperduto","doi":"10.1016/j.lungcan.2026.109317","DOIUrl":"10.1016/j.lungcan.2026.109317","url":null,"abstract":"<div><div>Brain metastases (BM) occur in 30–50% of non-small cell lung cancer (NSCLC) and up to 80% of small cell lung cancer (SCLC) patients, yet historically over 80% of clinical trials excluded this population. Current eligibility requirements often mandate completion of radiation therapy with prolonged washout periods, delaying systemic therapy initiation and limiting trial generalizability. Despite recommendations from ASCO-Friends of Cancer Research and FDA guidance, only 11.4% of lung cancer trials include patients with active, untreated BM.</div><div>We propose incorporating the Graded Prognostic Assessment (GPA) to standardize and broaden clinical trial enrollment. The 2022 Lung GPA, validated in 4,183 patients, incorporates age, Karnofsky Performance Status, extracranial metastases, number of BM, and molecular markers (EGFR, ALK, PD-L1 for NSCLC).</div><div>The GPA-based Eligibility Quotient (EQ) uses conditional probability to determine trial eligibility for patients with previously treated BM. We recommend including patients with GPA-predicted median survival ≥ 12 months or EQ ≥ 0.50. For asymptomatic, untreated BM, enrollment should be permitted with protocol-specified CNS imaging at 4–6-week intervals, reserving radiation for progression or inadequate response. Trials should stratify by GPA category, specify RANO-BM or modified RECIST criteria prospectively, and report both full analysis sets and evaluable CNS disease subsets. This evidence-based framework ensures patients with BM gain timely access to potentially life-extending therapies while maintaining trial integrity.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109317"},"PeriodicalIF":4.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting","authors":"Ryosuke Tsugitomi ,&nbsp;Kento Takagi ,&nbsp;Go Saito ,&nbsp;Motoko Tachihara ,&nbsp;Hironori Ashinuma ,&nbsp;Takehito Shukuya ,&nbsp;Shinnosuke Takemoto ,&nbsp;Shinya Sakata ,&nbsp;Atsuto Mouri ,&nbsp;Hideki Miwa ,&nbsp;Yosuke Tamura ,&nbsp;Takaaki Tokito ,&nbsp;Yoko Tsukita ,&nbsp;Yoshihito Kogure ,&nbsp;Takeshi Masuda ,&nbsp;Hiroshi Tanaka ,&nbsp;Sousuke Kubo ,&nbsp;Takaaki Sasaki ,&nbsp;Tomohiro Oba ,&nbsp;Nobuaki Mamesaya ,&nbsp;Takuji Suzuki","doi":"10.1016/j.lungcan.2026.109309","DOIUrl":"10.1016/j.lungcan.2026.109309","url":null,"abstract":"<div><h3>Background</h3><div>Thymic carcinoma is a rare thoracic malignancy with limited first-line treatment options. Lenvatinib has shown efficacy and tolerability in previously treated patients, but its role in chemotherapy-naive patients is unclear.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age.</div></div><div><h3>Results</h3><div>Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5–27.1). ORR was 50% (90% confidence interval [CI], 27.2–72.8%), and DCR 85% (95% CI, 62.1–96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6–17.1), 8.9 months (95% CI, 5.3–17.8), and 25.0 months (95% CI, 21.2–not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109309"},"PeriodicalIF":4.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer","authors":"Kazumasa Akagi ,&nbsp;Hirokazu Taniguchi ,&nbsp;Minoru Fukuda ,&nbsp;Takuya Yamazaki ,&nbsp;Daisuke Takao ,&nbsp;Ryuta Tagawa ,&nbsp;Fumiko Hayashi ,&nbsp;Ryosuke Ogata ,&nbsp;Sawana Ono ,&nbsp;Hiromi Tomono ,&nbsp;Takayuki Suyama ,&nbsp;Noritaka Honda ,&nbsp;Yasuhiro Umeyama ,&nbsp;Yosuke Dotsu ,&nbsp;Midori Matsuo ,&nbsp;Hiroshi Gyotoku ,&nbsp;Hiroaki Senju ,&nbsp;Shinnosuke Takemoto ,&nbsp;Hiroshi Soda ,&nbsp;Takashi Mizowaki ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.lungcan.2026.109310","DOIUrl":"10.1016/j.lungcan.2026.109310","url":null,"abstract":"<div><h3>Background</h3><div>Etoposide plus cisplatin (EP) with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) remains the standard treatment for unresectable limited-stage (LS) small cell lung cancer (SCLC)) for over two decades. Our previous study demonstrated that amrubicin plus cisplatin (AP) with once-daily thoracic radiotherapy (50 Gy per 25 fractions) for LS-SCLC prolonged overall survival (OS) to 39.5 months with manageable toxicities. To enhance therapeutic efficacy, this study aimed to assess the feasibility of AP combined with AHTRT for LS-SCLC.</div></div><div><h3>Methods</h3><div>Treatment-naïve patients aged 20–75 years with LS-SCLC, performance status 0–1, and adequate organ function were enrolled. Chemotherapy consisted of cisplatin 60 mg/m²/day (day 1) and amrubicin (days 1–3), administered concurrently with AHTRT (1.5 Gy/time, twice daily, 45 Gy in total). The initial amrubicin dose was set to 25 mg/m² and increased to 35 mg/m² from the second cycle.</div></div><div><h3>Results</h3><div>Nine patients were enrolled in this study. Dose-limiting toxicities included Grade 3 febrile neutropenia and Grade 3 hypokalemia. The recommended and maximum tolerated dose of amrubicin was 25 mg/m². The overall response rate was 100%, with both median progression-free survival and OS not reached. The 5-year OS rate was 64.8%.</div></div><div><h3>Conclusion</h3><div>AP combined with AHTRT from the first chemotherapy cycle was well tolerated at the recommended amrubicin dose of 25 mg/m². This regimen demonstrated promising efficacy and may represent a potential therapeutic option for LS-SCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109310"},"PeriodicalIF":4.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer","authors":"Alissa J. Cooper ,&nbsp;Joyce Liang ,&nbsp;Stephanie McDonald ,&nbsp;Andrea Arfe ,&nbsp;Wiktoria Bogdanska ,&nbsp;Jessica S. Ross ,&nbsp;Julia Rivera ,&nbsp;Phoebe Clark ,&nbsp;Shin Saito ,&nbsp;Bobby Daly ,&nbsp;Justin F. Gainor ,&nbsp;Charles M. Rudin ,&nbsp;Jacob Sands ,&nbsp;Catherine B. Meador","doi":"10.1016/j.lungcan.2026.109390","DOIUrl":"10.1016/j.lungcan.2026.109390","url":null,"abstract":"<div><h3>Background</h3><div>Tarlatamab has revolutionized the management of small cell lung cancer (SCLC) and is now a standard of care second-line therapy. Adoption of tarlatamab after FDA approval in the US has been rapid. However, real-world outcomes for patients who would not have met eligibility criteria for the clinical trials evaluating tarlatamab is not well-understood.</div></div><div><h3>Methods</h3><div>We designed a multicenter retrospective cohort study of three US institutions evaluating patients with SCLC who had received at least one dose of tarlatamab between 5/16/2024 and 6/15/2025. “Trial-ineligible” population was defined as patients with ECOG performance status ≥ 2, history of grade ≥ 2 pneumonitis or interstitial lung disease, untreated brain metastases, organ dysfunction, oxygen requirement or pleural effusion, history of stroke in past 12 months, or ejection fraction &lt; 50%. Primary study outcomes were measures of efficacy including best overall response per investigator and median time on treatment and measures of toxicity including incidence and severity of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity (ICANS).</div></div><div><h3>Results</h3><div>102 patients were identified. Median age was 64; patients were mostly white (92%) with a current or former tobacco use history (94%). 60 patients (59%) would have been ineligible for trial. Of patients evaluable for response (n = 80), eligible patients (n = 34) were more likely to have partial response or stable disease (70%), whereas ineligible patients were more likely to have progressive disease (57%), <em>p</em> = 0.047. Eligible patients had longer median time on treatment (4.8 months (95% CI 3.1-NR) vs 2.1 months (95% CI 1.6–5.6), <em>p</em> = 0.06. There was no difference in CRS incidence between groups (63% vs 59%, <em>p</em> = 0.8), but ICANS was more common in the ineligible group (33% vs 14%, <em>p</em> = 0.038).</div></div><div><h3>Conclusions</h3><div>Tarlatamab may be broadly applied for patients not eligible for trial enrollment, though with potential for lower efficacy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"216 ","pages":"Article 109390"},"PeriodicalIF":4.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer","authors":"Debora Brascia ,&nbsp;Giuseppe Mangiameli ,&nbsp;Maria Teresa Congedo ,&nbsp;Maria Giovanna Mastromarino ,&nbsp;Chiara Catelli ,&nbsp;Marco Schiavon ,&nbsp;Veronica Giudici ,&nbsp;Alessia Senatore ,&nbsp;Alessandro Bonis ,&nbsp;Marco Lucchi ,&nbsp;Luca Luzzi ,&nbsp;Stefano Magaritora ,&nbsp;Federico Rea ,&nbsp;Giuseppe Marulli","doi":"10.1016/j.lungcan.2026.108946","DOIUrl":"10.1016/j.lungcan.2026.108946","url":null,"abstract":"<div><h3>Objectives</h3><div>Non–small-cell lung cancer (NSCLC) diagnosed before the age of 50 is uncommon and remains poorly characterized from a prognostic perspective. This study aimed to identify clinical, pathological, and inflammatory–immune predictors of recurrence, early recurrence, and brain metastasis after curative resection in young patients.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study included 224 consecutive patients aged &lt;50 years who underwent anatomical lung resection between 2015 and 2024 at five Italian centers. Recurrence-free survival (RFS) was analyzed using Fine–Gray competing-risk regression and overall survival (OS) using Cox proportional hazards models. Early recurrence was defined as occurring within 12 months after surgery. The prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR), PD-L1 expression, and their combined phenotypes was explored. An exploratory ROC-derived NLR cut-off of 2.35 was used for stratification.</div></div><div><h3>Results</h3><div>During follow-up, 65 patients (29.0%) experienced recurrence, with brain metastases representing the most frequent distant site (10.3% overall). Early recurrence occurred in 11.6% of patients. On multivariable analysis, higher NLR independently predicted recurrence (sHR 1.37, 95% CI 1.09–1.73), mortality (HR 1.82, 95% CI 1.27–2.61), and early recurrence (OR 3.61, 95% CI 1.07–12.21). PD-L1 expression alone was not prognostic; however, when combined with NLR, it identified inflammatory–immunologic phenotypes with different risks of brain metastasis among patients who recurred (p = 0.051).</div></div><div><h3>Conclusions</h3><div>Young-onset NSCLC is characterized by a high burden of early and distant recurrence, particularly involving the brain. Preoperative NLR is a robust predictor of recurrence, early relapse, and mortality. Combined NLR–PD-L1 phenotypes identify a subgroup at increased risk of neurotropic relapse.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108946"},"PeriodicalIF":4.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological features and quality of life in low-dose CT lung cancer screening: a comparative analysis with general population data","authors":"Wei-Chia Huang ,&nbsp;Tzu-Ning Kao ,&nbsp;Shih-Cheng Liao ,&nbsp;Mong-Wei Lin ,&nbsp;Wei-Lieh Huang","doi":"10.1016/j.lungcan.2026.109307","DOIUrl":"10.1016/j.lungcan.2026.109307","url":null,"abstract":"<div><h3>Objective</h3><div>Concerns persist regarding the psychological effects of low dose computed tomography (LDCT) screening, with prior studies linking it to psychological distress and diminished quality of life (QoL). However, specific risk factors remain unclear. This study aimed to compare the psychological features of LDCT recipients with the general population and identify associated factors.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis was conducted using prospectively collected data from April 2022 to April 2023. Participants seeking second opinions at a tertiary medical center in Asia after LDCT screenings were recruited. We collected sociodemographic data, screening details, and self-administered questionnaires assessing somatic symptoms, health anxiety, depression, anxiety, and quality of life. Psychological conditions and QoL were compared between LDCT recipients and a general population cohort comprising 3161 individuals.</div></div><div><h3>Results</h3><div>We compared 201 LDCT recipients (30.8% male, mean age 56.6 years) with 3161 general population controls. Compared to the general population (adjusted for age and sex), LDCT recipients had significantly higher rates of somatic symptom disorder (28.9% vs. 5.0%, p &lt; 0.001), depression (16.4% vs. 5.7%, p &lt; 0.001), and anxiety (20.9% vs. 3.5%, p &lt; 0.001). Among 103 participants undergoing surgical intervention, 85.4% were diagnosed with malignant or precancerous lesions. The 3-year overall survival rate was 98.0%, indicating favorable clinical outcomes.</div></div><div><h3>Conclusion</h3><div>LDCT recipients in an Asian population exhibited a higher prevalence of psychological distress than the general population. Close monitoring is essential, especially among those with pre-existing mental health issues. Future longitudinal studies are needed to elucidate long-term psychological outcomes of LDCT screening.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 109307"},"PeriodicalIF":4.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic profiling of early-stage non-small cell lung cancer identifies a high-performance protein signature associated with postoperative recurrence","authors":"Ying Huang ,&nbsp;Qiuhua Deng ,&nbsp;Jie Li ,&nbsp;Runchen Wang ,&nbsp;Zhen Li ,&nbsp;Liping Liu ,&nbsp;Lei Song ,&nbsp;Xiaohong Zhao ,&nbsp;Liyan Huang ,&nbsp;Haihong Yang ,&nbsp;Weiqiang Yin","doi":"10.1016/j.lungcan.2026.108907","DOIUrl":"10.1016/j.lungcan.2026.108907","url":null,"abstract":"<div><h3>Background</h3><div>The 5-year recurrence rate remains significantly high (∼30 %) in patients with early-stage Non-Small Cell Lung Cancer (NSCLC), even after complete tumor resection. Recurrence prediction primarily relies on pathological assessment and genomic abnormalities. However, proteins — the functional executors of genetic information — may offer additional prognostic value. In this study, we aimed to develop a model integrating proteomic and clinical features to improve recurrence prediction in early-stage NSCLC.</div></div><div><h3>Methods</h3><div>We recruited 351 stage Ⅰ NSCLC patients who underwent radical surgery in discovery corhort. An additional 103 participants from external prospective cohort were used for validation. Clinical data and follow-up outcomes were retrospectively collected. Tumor proteomics profiling was performed using liquid chromatography-mass spectrometry (LC-MS/MS). The proteomics data were acquired using a data-independent acquisition mode with a 150-minute gradient method and analyzed against the human UniProt database using DIA-NN (v1.8.1). We assessed the association between proteomic and clinicopathologic factors and disease-free survival (DFS) using Cox proportional hazards regression. A receiver operating characteristic (ROC) curve analysis was used to construct the predictive model.</div></div><div><h3>Results</h3><div>Of the 351 patients analyzed, 4260 differentially expressed proteins (DEPs) were identified as being associated with tumor recurrence. A nine-protein prediction model outperformed the clinicopathologic-based model (AUC, 0.898 vs. 0.742; <em>P</em> &lt; 0.001) in predicting DFS. A combined model incorporating nine proteins and clinicopathological features demonstrated excellent predictive value for 5-year recurrence in the discovery cohort (AUC = 0.896). Nine proteins combined with clinicopathological features showed an AUC of 0.810 in the external validation cohort and an AUC of 0.844 in the combined cohort.</div></div><div><h3>Conclusion</h3><div>Integrating tumor proteomics with clinicopathologic features enhances risk stratification and improves recurrence prediction after surgical resection of early-stage NSCLC. This approach may enable more personalized postoperative management through refined surveillance intervals and potential adjuvant therapies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108907"},"PeriodicalIF":4.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic landscape of stage 0–IA lung adenocarcinoma identified by on-site reflex targeted NGS","authors":"Marius Ilié ,&nbsp;Simon Heeke ,&nbsp;Guylène Rignol ,&nbsp;Radu Pirlog ,&nbsp;Samantha Goffinet ,&nbsp;Elodie Long-Mira ,&nbsp;Sandra Lassalle ,&nbsp;Virginie Lespinet-Fabre ,&nbsp;Olivier Bordone ,&nbsp;Virginie Tanga ,&nbsp;Caroline Lacoux ,&nbsp;Christelle Bonnetaud ,&nbsp;Jonathan Benzaquen ,&nbsp;Jacques Boutros ,&nbsp;Charlotte Cohen ,&nbsp;Abel Gomez-Caro ,&nbsp;Charles Hugo Marquette ,&nbsp;Jean-Philippe Berthet ,&nbsp;Véronique Hofman ,&nbsp;Paul Hofman","doi":"10.1016/j.lungcan.2026.108943","DOIUrl":"10.1016/j.lungcan.2026.108943","url":null,"abstract":"<div><h3>Introduction</h3><div>Early molecular profiling in non-squamous non-small cell lung carcinoma (NSCLC), particularly lung adenocarcinoma (LUAD), is critical for guiding individualized treatment strategies. Limited data exist on the genomic landscape of Stage 0–IA LUAD. This study assessed the feasibility and clinical relevance of reflex targeted next-generation sequencing (NGS) performed on-site at diagnosis in resected early-stage LUAD.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 239 consecutive Stage 0–IA LUAD cases diagnosed between 2022 and 2024 at a single institution. Ultra-fast reflex DNA- and RNA-based NGS was performed on resected specimens using a 50-gene targeted panel. Alterations were classified according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Associations between genomic alterations, histologic subtypes, and tumor grades were evaluated.</div></div><div><h3>Results</h3><div>Stage IA1 was the most frequent diagnosis (46%). High-quality sequencing data were obtained in all cases, with a median turnaround time of 102 h. At least one genomic alteration was detected in 80% of tumors. <em>KRAS</em> mutations were most frequent (35.8%), including <em>KRAS</em> G12C in 16%. <em>EGFR</em> mutations were present in 27.2%, primarily classical sensitizing alterations. Other actionable findings included <em>ALK</em> fusions (3.3%), <em>RET</em> rearrangements (1.2%), <em>MET</em> exon 14 skipping (2.4%), <em>HER2</em> mutations (3.7%), and <em>BRAF</em> V600E (0.8%). ESCAT Level I alterations were found in 34% of tumors; 20% of these co-occurred with <em>TP53</em> mutations. Significant associations were observed between genomic alterations, histologic subtypes, and tumor grades.</div></div><div><h3>Conclusions</h3><div>Reflex NGS at diagnosis in resected Stage 0–IA LUAD is feasible, rapid, and reveals a high rate of actionable alterations, which may support its integration in the future into early-stage diagnostic workflows.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108943"},"PeriodicalIF":4.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}